GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stayble Therapeutics AB (OSTO:STABL) » Definitions » Pretax Margin %

Stayble Therapeutics AB (OSTO:STABL) Pretax Margin % : % (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Stayble Therapeutics AB Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Stayble Therapeutics AB's Pre-Tax Income for the three months ended in Sep. 2023 was kr-7.04 Mil. Stayble Therapeutics AB's Revenue for the three months ended in Sep. 2023 was kr0.00 Mil. Therefore, Stayble Therapeutics AB's pretax margin for the quarter that ended in Sep. 2023 was %.

The historical rank and industry rank for Stayble Therapeutics AB's Pretax Margin % or its related term are showing as below:


OSTO:STABL's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -155.67
* Ranked among companies with meaningful Pretax Margin % only.

Stayble Therapeutics AB Pretax Margin % Historical Data

The historical data trend for Stayble Therapeutics AB's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stayble Therapeutics AB Pretax Margin % Chart

Stayble Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Pretax Margin %
Get a 7-Day Free Trial - - - - -

Stayble Therapeutics AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Stayble Therapeutics AB's Pretax Margin %

For the Biotechnology subindustry, Stayble Therapeutics AB's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stayble Therapeutics AB's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stayble Therapeutics AB's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Stayble Therapeutics AB's Pretax Margin % falls into.



Stayble Therapeutics AB Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Stayble Therapeutics AB's Pretax Margin for the fiscal year that ended in Dec. 2022 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-24.526/0
= %

Stayble Therapeutics AB's Pretax Margin for the quarter that ended in Sep. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=-7.043/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stayble Therapeutics AB  (OSTO:STABL) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Stayble Therapeutics AB Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Stayble Therapeutics AB's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Stayble Therapeutics AB (OSTO:STABL) Business Description

Traded in Other Exchanges
Address
Medicinaregatan 8a, Gothenburg, SWE, SE-413 90
Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.

Stayble Therapeutics AB (OSTO:STABL) Headlines

No Headlines